Moreover, a number of preclinical studies indicate that these molecules are able to determine an antitumor immune response, evidenced by the combination with immune checkpoint blockade, targeting pathways such as the programmed cell death protein-1 (PD-1) axis resulting in a synergistic effect on tumor growth [98]. This evidence concerns the gene PDCD1 and neoplasm.